MedTrace Logo

A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance

NCT02849444 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 326

Last updated 2021-08-16

No results posted yet for this study

Summary

A prospective, multicentre, post-authorisation observational study. The objective of this study is assess the response of renal function in clinical practice to anti-multiple myeloma therapy in patients with relapsed MM and CrCl \<50 mL/min/1.73 m2.

Conditions

Interventions

OTHER

Anti-myeloma treatment at physician discretion

non Interventional Study

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Mireya Navarro, MD · Celgene Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-23
Primary Completion
2019-12-23
Completion
2020-12-10

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02849444 on ClinicalTrials.gov